Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SQUIBB/SANKYO ANTI-CHOLESTEROL AGENT CS-514 TO ENTER U.S CLINICIALS

Executive Summary

SQUIBB/SANKYO ANTI-CHOLESTEROL AGENT CS-514 TO ENTER U.S CLINICIALS within the next few months, Squibb announced in a July 18 press release. The drug, which inhibits an enzyme in the biosynthetic process of making cholesterol, was developed by Sankyo and is being licensed to Squibb for worldwide marketing except in Japan, Korea, Taiwan and Thailand, Squibb said. The release noted that Sankyo will "retain the right to market the drug in the licensed markets at a future time" Commenting on the agreement, Squibb President and CEO Dennis Fill said: "We are gratified that our 25-year relationship with Sankyo continues to grow in importance to both companies. This agreement furthers the development of one of our key strategic goals, namely, to increase our contribution to cardiovascular medicine." Squibb said that CS-514 is similar to, and will compete with, Merck's mevinolin, which is also in clinical trials. Sankyo presently markets Squibb's ACE inhibitor Capoten (captopril) in Japan along with two other Squibb antibiotics, Velosef and Kenalog. According to a Squibb spokesman, the licensing agreement covering CS-514 marks the first time that the licensing relationship between the firms will bring a Sankyo product to the U.S.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel